Table 1.
Demographics of kidney transplant recipients in the Belatacept Early Steroid Withdrawal Trial
| Characteristics | Group A Alemtuzumab/Belatacept |
Group B rATG/Belatacept |
Group C rATG/Tacrolimus |
| Recipients, n | 107 | 104 | 105 |
| Age (yr) at transplant, median (IQR) | 54 (43–60) | 53 (45–60) | 51 (42–63) |
| Female sex, n (%) | 30 (28) | 38 (37) | 36 (34) |
| Race, n (%) | |||
| White | 82 (77) | 88 (85) | 80 (76) |
| Black | 12 (11) | 11 (11) | 19 (18) |
| Asian | 5 (5) | 0 (0) | 0 (0) |
| American Indian or Alaskan Native | 3 (3) | 1 (1) | 1 (1) |
| Other | 5 (5) | 4 (4) | 5 (5) |
| Ethnicity (Hispanic or Latino), n (%) | 8 (8) | 5 (5) | 8 (8) |
| Kidney failure etiology, n (%) | |||
| Hypertension | 22 (21) | 16 (15) | 16 (15) |
| Diabetes mellitus | 20 (19) | 21 (20) | 21 (20) |
| Polycystic kidney disease | 25 (23) | 24 (23) | 21 (20) |
| GN | 8 (8) | 9 (9) | 7 (7) |
| SLE | 0 (0) | 0 (0) | 3 (3) |
| FSGS | 7 (7) | 4 (4) | 5 (5) |
| IgA nephropathy | 9 (8) | 7 (7) | 7 (7) |
| Obstructive disorder/reflux | 3 (3) | 0 (0) | 3 (3) |
| Unknown | 3 (3) | 3 (3) | 3 (3) |
| Other | 10 (9) | 20 (19) | 19 (18) |
| Donor type, n (%) | |||
| Living related donor | 25 (23) | 25 (24) | 33 (31) |
| Living unrelated donor | 55 (51) | 53 (51) | 47 (45) |
| Deceased donor | 27 (25) | 26 (25) | 25 (24) |
| Pre-emptive transplant, n (%) | 37 (35) | 27 (26) | 40 (39) |
| Repeat transplant, n (%) | 7 (7) | 2 (2) | 3 (3) |
| HLA-A mismatches, n (%) | |||
| 0 | 9 (8) | 7 (7) | 7 (7) |
| 1 | 52 (49) | 53 (51) | 55 (52) |
| 2 | 46 (43) | 44 (42) | 43 (41) |
| HLA-B mismatches, n (%) | |||
| 0 | 5 (5) | 3 (3) | 4 (4) |
| 1 | 42 (39) | 37 (36) | 50 (48) |
| 2 | 60 (56) | 64 (62) | 51 (49) |
| HLA-DR mismatches, n (%) | |||
| 0 | 7 (7) | 6 (6) | 14 (13) |
| 1 | 45 (42) | 56 (54) | 53 (51) |
| 2 | 55 (51) | 42 (40) | 38 (36) |
| HLA-DQ mismatches, n (%) | |||
| 0 | 15 (14) | 16 (15) | 17 (16) |
| 1 | 52 (49) | 48 (46) | 57 (54) |
| 2 | 40 (37) | 40 (39) | 31 (30) |
| Pretransplant cPRA (%) | |||
| N | 103 | 101 | 102 |
| Median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Min, max | 0, 57 | 0, 79 | 0, 91 |
| Preexisting DSA, n (%) | 1 (1) | 4 (4) | 0 (0) |
| Deceased-donor cold ischemia time (h) | |||
| N | 21 | 22 | 20 |
| Median (IQR) | 12 (11–16) | 12 (10–17) | 13 (8–18) |
| CMV donor/recipient serology, n (%) | |||
| D+R− | 18 (17) | 21/103 (20) | 25 (24) |
| D+R+ | 37 (35) | 28/103 (27) | 33 (31) |
| D−R+ | 17 (16) | 19/103 (19) | 14 (13) |
| D−R− | 35 (33) | 35/103 (34) | 33 (31) |
| Diabetes mellitus, n (%) | |||
| Type 1 | 2 (2) | 2 (2) | 6 (6) |
| Type 2 | 24 (22) | 31 (30) | 27 (26) |
| Pretransplant BMI (kg/m2), median (IQR) | 28 (24–32) | 28 (26–31) | 28 (25–32) |
| Framingham risk score, median (IQR) | 5 (1–7) | 5 (2–8) | 5 (1–8) |
| Donor data | |||
| Female donor sex, n (%) | 65 (61) | 63 (61) | 64 (61) |
| Donor age (yr), median (IQR) | 45 (32–53) | 42 (31–50) | 40 (31–48) |
| Donor race, n (%) | |||
| White | 100 (94) | 95 (91) | 95 (91) |
| Black | 3 (3) | 4 (4) | 4 (4) |
| American Indian or Alaska Native | 0 (0) | 1 (1) | 1 (1) |
| Asian | 1 (1) | 2 (2) | 0 (0) |
| Other | 2 (2) | 2 (2) | 5 (5) |
| History of hypertension, n (%) | |||
| Positive | 10 (9) | 10 (10) | 11 (11) |
| Negative | 89 (83) | 87 (84) | 85 (81) |
| N/A | 8 (8) | 7 (7) | 9 (9) |
| CVA as cause of death, n (%) | |||
| Yes | 5 (5) | 1 (1) | 3 (3) |
| No | 21 (20) | 27 (26) | 23 (22) |
| N/A | 81 (76) | 76 (73) | 79 (75) |
| Terminal creatinine >1.5 mg/dl2, n (%) | |||
| Yes | 1 (1) | 4 (4) | 3 (3) |
| No | 32 (30) | 27 (26) | 29 (28) |
| N/A | 74 (69) | 73 (70) | 73 (70) |
rATG, rabbit anti-thymocyte globulin; IQR, interquartile range; cPRA, calculated panel-reactive antibody; min, minimum; max, maximum; DSA, donor-specific antibodies; CMV, cytomegalovirus; BMI, body mass index; N/A, not available; CVA, cerebrovascular accident; D, donor; R, recipient.